Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2017/V14/I6/379

[1] 赵梁艳，廖俊辉，吴海兰. 匹伐他汀钙致横纹肌溶解1例[J]. 中国药物警戒，2014，11（10）：635-635.
[2] Zutt R, van der Kooi A J, Linthorst G E, et al. Rhabdomyolysis: review of the literature[J]. Neuromuscul Disord, 2014, 24(8):651-659.
[3] N?gele H, Behrens S, Hashagen S, et al. Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy[J]. Drug Metabol Drug Interact, 2007, 22(2-3):195-200.
[4] Ricaurte B, Guirguis A, Taylor H C, et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity[J]. Ann Pharmacother, 2006, 40(4):753-757.
[5] Roten L, Schoenenberger R A, Kr?henbühl S, et al. Rhabdomyolysis in association with simvastatin and amiodarone[J]. Ann Pharmacother, 2004, 38(6):978-981.
[6] Saliba W R, Elias M. Myopathy from the combination of simvastatin and amiodarone[J]. Eur J Intern Med, 2006,17(2):148.
[7] Semmo M, Dhayat N A. Gluteal rhabdomyolysis and renal failure due to simvastatin and amiodarone[J]. Kidney Int, 2016, 90(4):909.
[8] 药品不良反应信息通报.警惕辛伐他汀与胺碘酮联合使用或高剂量使用增加横纹肌溶解发生风险[J]. 中国执业药师，2010，7（12）：13-14.
[9] 姜玲海，张军，方忠宏. 药源性横纹肌溶解症高危因素研究[J]. 中国药房，2015，26（29）：4082-4086.
[10] Sakamoto K, Kimura J. Mechanism of statin-induced rhabdomyolysis[J]. J Pharmacol Sci, 2013, 123(4):289-294.
[11] Boonmuang P, Nathisuwan S, Chaiyakunapruk N, et al. Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database[J]. Drug Saf, 2013, 36(9):779-787.
[12] Florentin M, Elisaf M S. Simvastatin interactions with other drugs[J]. Expert Opin Drug Saf, 2012, 11(3):439-444.
[13] Hirota T, Ieiri I. Drug-drug interactions that interfere with statin metabolism[J]. Expert Opin Drug Metab Toxicol, 2015, 11(9):1435-1447.
[14] Page S R, Yee K C. Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin[J]. Intern Med J, 2014, 44(7):690-693.
[15] Kanter C T, Luin M V, Solas C, et al. Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin[J]. Ann Hepatol, 2014, 13(4):452-455.
[16] DeDea L. Simvastatin dosing restrictions; monitoring amiodarone therapy[J]. JAAPA, 2011, 24(9):16.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.